 Codexis Inc NASDAQ: CDXS raised its guidance for 2021 following the receipt of a binding purchase order for up to 13.9 million of a proprietary high-performance enzyme product from an undisclosed pharmaceutical company. Now, the Company expects 2021 total revenues in the range of 89 million to 93 million, up from previous guidance of 82 million to 85 million, higher than the 83.7 million consensus. 